依达拉奉联合灯盏花素治疗急性脑梗死的临床观察

目的：观察依达拉奉联合灯盏花素治疗急性脑梗死的临床疗效和安全性。方法：将97例急性脑梗死患者随机分为治疗组48例和对照组49例。对照组予复方丹参注射液20mL加入生理盐水250mL中静脉滴注，1次／d；同时，采用生理盐水15mL加生理盐水250mL静脉滴注，2次／d，均连用14d。治疗组予注射用灯盏花素50mg加入生理盐水250mL中静脉滴注，1次／d；另用依达拉奉注射液30mg加入生理盐水250mL中静脉滴注，2次／d，连用14d。结果：治疗组在治疗后第7、14、21d的神经功能改善程度均显著优于对照组（P〈0．05）。治疗组的显效率（70．8％）明显高于对照组（40．8％）（P〈0．01）；治疗组的总有效率（91．7％）与对照组（63．3％）比较，差异有统计学意义（P〈0．01）。两组在治疗后90d MRS评分均有所改善，但治疗组改善更明显（P〈0．05）。治疗组未见明显副作用。结论：依达拉奉与灯盏花素联用能有效改善急性脑梗死患者的神经功能和生活能力。

Clinical observation on combining edaravone with breviscapine in treatment of patients with acute cerebral infarction

To investigate the clinical effect and safety of combining edaravone with breviscapine in treatment of patients with acute cerebral infarction (ACI). METHODS: Ninety-seven ACI cases were randomly divided into treatment group and control group. The control group receiving the treatment of Fu-fang Danshen injection 20 mL + 0.9% NS 250 mL iv gtt qd and 0.9% NS 15 mL + 0.9% NS 250 mL iv gtt b. i. d for 14d, while the treatment group was treated with breviscapine injection 50 mg + 0.9 % NS 250 mL iv gtt qd and edaravone injection 30 mg + 0.9% NS 250 mL iv gtt b. i. d for 14 d. RESULTS: The im-provement of the clinic neurological function deficient score at 7, 14 and 21 d after treatment in treatment group was obviously better than that in control group (P < 0.05 ) . The improving rate in treatment group was significantly higher than that in control group (70.8 % vs 40.8% , P < 0.01). The total effective rate in treatment group was significantly higher than that in control group (91.7% vs 63.3%, P<0.01). The score of MRS in two groups were improved at 90 d after treatment, but the improvement in treatment group was more obvious( P < 0.05) . The treatment group had few side effect occurred. CONCLUSION: Combining edaravone with breviscapine can effectively improve the neurological function and the living ability of patients with ACI.